3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Liposarcoma
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Gastro-enteropancreatic neuroendocrine tumor
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
13
Cisplatin
10
pembrolizumab
7
Oxaliplatin
5
Leucovorin
5
Fluorouracil
5
durvalumab
4
Paclitaxel
4
Nivolumab
3
Injections
3
Immune Checkpoint Inhibitors
3
Capecitabine
3
camrelizumab
2
Docetaxel
2
Cetuximab
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
surufatinib
1
spartalizumab
1
silmitasertib
1
regorafenib
1
pertuzumab
1
manganese chloride
1
lenvatinib
1
irinotecan sucrosofate
1
folfirinox
1
devimistat
1
derazantinib
1
binimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Biliary Tract Neoplasms
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled